Literature DB >> 10823306

Cognitive impairment in schizophrenia: its impact on social functioning.

P F Liddle1.   

Abstract

OBJECTIVE: To examine cognitive impairment in schizophrenia and its impact on social functioning.
METHOD: Cohort studies recording cognitive and social development, studies of predictors of poor community outcome, and evidence from brain imaging studies are reviewed.
RESULTS: Executive function deficits, and poor performance in verbal memory, vigilance, and working memory tests are strong predictors of poor community outcome and impairment in skills learning. PET scans of regional cerebral blood flow suggest a dynamic imbalance between different cerebral areas rather than overall loss of brain function.
CONCLUSION: Chronic cognitive impairment is the strongest predictor of social disability. Results suggest that the impairment of brain function associated with executive deficits is not necessarily irreversible and may therefore be treatable with appropriate drug therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823306     DOI: 10.1111/j.0065-1591.2000.007s021[dash]3.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  27 in total

1.  Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status.

Authors:  Kate B Carey; Michael P Carey; Jeffrey S Simons
Journal:  J Nerv Ment Dis       Date:  2003-05       Impact factor: 2.254

2.  The feasibility of cognitive adaptation training for outpatients with schizophrenia in integrated treatment.

Authors:  Jens Peter Hansen; Birte Østergaard; Merete Nordentoft; Lise Hounsgaard
Journal:  Community Ment Health J       Date:  2012-10-12

3.  Differentiating between clinical and behavioral phenotypes in first-episode psychosis during maintenance of visuospatial working memory.

Authors:  Maria Jalbrzikowski; Vishnu P Murty; Patricia L Stan; Jusmita Saifullan; Daniel Simmonds; William Foran; Beatriz Luna
Journal:  Schizophr Res       Date:  2017-11-11       Impact factor: 4.939

Review 4.  [Social psychiatry and neurobiology : A long overdue convergence exemplified by schizophrenia].

Authors:  W Kawohl; C Wyss; P Roser; M Brüne; W Rössler; G Juckel
Journal:  Nervenarzt       Date:  2017-05       Impact factor: 1.214

5.  Integrated psychological therapy (IPT) for schizophrenia: is it effective?

Authors:  Volker Roder; Daniel R Mueller; Kim T Mueser; Hans D Brenner
Journal:  Schizophr Bull       Date:  2006-08-17       Impact factor: 9.306

6.  Eye gaze and pupillary response in Angelman syndrome.

Authors:  Michael P Hong; Janna L Guilfoyle; Lindsey N Mooney; Logan K Wink; Ernest V Pedapati; Rebecca C Shaffer; John A Sweeney; Craig A Erickson
Journal:  Res Dev Disabil       Date:  2017-07-24

7.  Habituation during encoding: A new approach to the evaluation of memory deficits in schizophrenia.

Authors:  Suzanne N Avery; Maureen McHugo; Kristan Armstrong; Jennifer U Blackford; Simon Vandekar; Neil D Woodward; Stephan Heckers
Journal:  Schizophr Res       Date:  2020-07-28       Impact factor: 4.939

8.  Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia.

Authors:  Jeffrey R Bishop; James L Reilly; Margret S H Harris; Shitalben R Patel; Rick Kittles; Judith A Badner; Konasale M Prasad; Vishwajit L Nimgaonkar; Matcheri S Keshavan; John A Sweeney
Journal:  Psychopharmacology (Berl)       Date:  2014-08-07       Impact factor: 4.530

Review 9.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

10.  Impact of vocational rehabilitation on social functioning, cognitive functioning, and psychopathology in patients with chronic schizophrenia.

Authors:  P N Suresh Kumar
Journal:  Indian J Psychiatry       Date:  2008-10       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.